The site offers API process development and manufacturing for oligonucleotides, peptides & conjugates from preclinical to commercial manufacturing.
The 74-acre campus offers a unique one-site solution for oligonucleotides, peptides, and related synthetic conjugates with approximately 30 oligonucleotide manufacturing lines at various scales and over 20 peptide production lines with a total solid phase peptide synthesis (SPPS) reactor volume over 20,000 L. When combining the peptide capacity in our Taixing site, the total reactor volume of solid-phase peptide synthesizers at WuXi TIDES has reached over 32,000 L.
Our Changzhou site has successfully passed numerous inspections by the US FDA, China NMPA, Japan PMDA, South Korea MFDS, and Brazil ANVISA. More specifically, the site recently passed a PAI for a new peptide drug from Japan PMDA.
